Journey Medical (NASDAQ:DERM) Issues Quarterly Earnings Results

Journey Medical (NASDAQ:DERM) posted its earnings results on Wednesday. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.30, Zacks reports. The firm had revenue of $14.30 million during the quarter, compared to analysts’ expectations of $14.21 million. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%.

Journey Medical Stock Up 1.2 %

Shares of NASDAQ:DERM traded up $0.07 during trading on Friday, reaching $5.99. 21,587 shares of the company traded hands, compared to its average volume of 86,303. The firm has a fifty day simple moving average of $5.05 and a 200 day simple moving average of $5.16. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. Journey Medical has a 1-year low of $3.20 and a 1-year high of $6.89. The firm has a market cap of $125.13 million, a P/E ratio of -6.37 and a beta of 0.97.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Journey Medical in a research report on Thursday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $9.67.

Insider Buying and Selling at Journey Medical

In other Journey Medical news, CEO Claude Maraoui sold 49,271 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total transaction of $246,847.71. Following the transaction, the chief executive officer now owns 2,003,147 shares in the company, valued at $10,035,766.47. This trade represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 105,831 shares of company stock worth $536,622 over the last ninety days. 13.16% of the stock is currently owned by insiders.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.